查詢結果分析
來源資料
相關文獻
- Trimodality Treatment for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma
- 局部廣泛性食道癌--手術後同步化學放射治療
- Preliminary Results of Preoperative Chemoradiation Therapy for Cervical Esophageal Squamous Cell Carcinoma with Larynx Preservation
- Preoperative Chemoradiotherapy Followed by Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Single Center Experience in Southern Taiwan
- 食道癌之化學放射治療
- The Clinical Features and Surgical Results of Malignant Eyelid Tumors
- Post-Operative Combination of Radiotherapy and Chemotherapy in Esophageal Cancer
- Video-Assisted Thoracoscopic Surgery for Early Cancer of the Thoracic Esophagus
- Laparoscopic Low Anterior Resection for Selected Mid and Low Rectal Cancers
- 胸部食道癌的新手術方法
頁籤選單縮合
題 名 | Trimodality Treatment for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma=術前化學放射治療合併手術使用於局部晚期可切除之食道鱗狀細胞癌的成效 |
---|---|
作 者 | 陳彥豪; 呂宏益; 黃承華; 饒坤銘; 邱逸群; 王友明; 陳彥仰; 劉建廷; 李劭軒; | 書刊名 | 臺灣癌症醫學雜誌 |
卷 期 | 27:5 2011.10[民100.10] |
頁 次 | 頁200-210 |
分類號 | 416.241 |
關鍵詞 | 化學放射治療; 手術; 食道癌; 鱗狀細胞癌; Concurrent chemoradiotherapy; Surgery; Esophageal cancer; Squamous cell carcinoma; |
語 文 | 英文(English) |
中文摘要 | 目的:食道鱗狀細胞癌的病人預後極差。食道切除合併淋巴結廓清是過去主要的治療方 式,但近年來術前化學放射治療合併手術(三重療法)已逐漸在臨床上使用。藉此研究,我 們想要探討三重療法或單一手術對局部晚期可切除之食道鱗狀細胞癌的治療效果及併發 症。 方法:102 位局部晚期可切除之食道鱗狀細胞癌病患於1991 年至2010 年在本院診斷。根 據治療方式將病人分為三重療法(41 人)或單一手術(61 人),並分析兩組的存活率及併發 症。 結果:平均追蹤時間為15 個月。單變項分析發現2003 年後治療(P<0.001)、三重療法(P= 0.006)及女性(P=0.017)為整體存活率及無病存活率之預測因子;在多變項分析中,三重療 法(P=0.006)及女性(P=0.040)仍然呈現存活率之優勢。兩組間的術後併發症並無差異。在 三重療法組中,8 位(20%)得到病理性完全緩解的病人有明顯之整體存活率(P=0.034)及無 病存活率(P=0.022)之改善。 結論:由於此結果為病歷回溯性研究,三重療法有較好之存活率優勢及兩組間之術後併 發症相似仍須前膽性的隨機對照試驗來證實。 |
英文摘要 | Background: Patients with esophageal squamous cell carcinoma have a poor prognosis. An esophagectomy with lymph node dissection was the standard treatment in the past, but preoperative chemoradiotherapy followed by surgery (trimodality) has become more common in clinical practice recently. The aim of this study is to report the treatment outcome and postoperative mortality/morbidities of these two treatment modalities in patients with locally advanced, resectable esophageal squamous cell carcinoma. Methods: Between January 1991 and December 2010, 102 patients with locally advanced, resectable stage (T3N0-1) esophageal squamous cell carcinoma who received trimodality treatment or surgery alone were identified. There were 41 patients in the trimodality group, and 61 patients in the group of surgery alone. The outcome and postoperative complications were compared between the trimodality group and the surgery-alone group. Results: The median follow-up from the time of diagnosis of the esophageal cancer was 15.0 months. A univariate analysis showed that treatment after 2003 (P<0.001), trimodality therapy (P=0.006), and female sex (P=0.017) were predictive of better disease-free survival and overall survival. In multivariate comparison, trimodality therapy (P=0.006) and female sex (P=0.040) represented the independent predictive factors of longer survival. Postoperative mortality and morbidities were similar between these two groups. In 41 patients receiving trimodality therapy, 8 (20%) patients achieved a complete pathologic response after preoperative chemoradiotherapy and had significantly superior overall survival (P=0.034) and disease-free survival (P=0.022). Conclusions: Retrospective and nonrandomized nature of this study did not allow comparison of trimodality therapy with surgery alone, the similar postoperative complications between surgery alone and trimodality groups, together with the improved survival in patients receiving trimodality therapy would support the need for additional prospective randomized controlled trial. |
本系統中英文摘要資訊取自各篇刊載內容。